Madrigal Pharmaceuticals has been granted a patent for methods of synthesizing pyridazinone compounds as thyroid hormone analogs and prodrugs. The patent also includes a method for treating fatty liver disease by administering a specific compound at a specified dosage range. GlobalData’s report on Madrigal Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Madrigal Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Madrigal Pharmaceuticals's grant share as of May 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of fatty liver disease using specific compound
A recently granted patent (Publication Number: US11986481B2) discloses a method for treating fatty liver disease, specifically nonalcoholic steatohepatitis, in a subject. The method involves administering a compound, 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, or its pharmaceutically acceptable salt, at a dosage ranging from about 20 mg to 100 mg per day. The compound can be administered orally, preferably in the form of a tablet, and with a purity of 95% or greater.
Furthermore, the patent also covers a method for treating fatty liver disease by administering a pharmaceutical composition containing the same compound mentioned earlier along with pharmaceutically acceptable excipients or carriers. This composition is suitable for oral administration at a dosage of 20 mg to 100 mg per day, preferably as a single dose. The compound in the composition should have a purity of 95% or greater, ensuring its effectiveness in treating the condition. The patent emphasizes the importance of the compound in addressing fatty liver disease, particularly nonalcoholic steatohepatitis, offering a specific dosage range and administration method for optimal results.
To know more about GlobalData’s detailed insights on Madrigal Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
